EA016884B1 - Способ предсказания агрегации белков и конструирования ингибиторов агрегации - Google Patents

Способ предсказания агрегации белков и конструирования ингибиторов агрегации Download PDF

Info

Publication number
EA016884B1
EA016884B1 EA200970180A EA200970180A EA016884B1 EA 016884 B1 EA016884 B1 EA 016884B1 EA 200970180 A EA200970180 A EA 200970180A EA 200970180 A EA200970180 A EA 200970180A EA 016884 B1 EA016884 B1 EA 016884B1
Authority
EA
Eurasian Patent Office
Prior art keywords
aggregation
protein
residues
peptide
peptide sequence
Prior art date
Application number
EA200970180A
Other languages
English (en)
Russian (ru)
Other versions
EA200970180A1 (ru
Inventor
Кай Й. Колхофф
Хесус Сурдо
Микеле Вендрусколо
Original Assignee
ЛОНЗА БАЙОЛОДЖИКС ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЛОНЗА БАЙОЛОДЖИКС ПиЭлСи filed Critical ЛОНЗА БАЙОЛОДЖИКС ПиЭлСи
Publication of EA200970180A1 publication Critical patent/EA200970180A1/ru
Publication of EA016884B1 publication Critical patent/EA016884B1/ru

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
EA200970180A 2006-08-04 2007-07-24 Способ предсказания агрегации белков и конструирования ингибиторов агрегации EA016884B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (2)

Publication Number Publication Date
EA200970180A1 EA200970180A1 (ru) 2009-08-28
EA016884B1 true EA016884B1 (ru) 2012-08-30

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970180A EA016884B1 (ru) 2006-08-04 2007-07-24 Способ предсказания агрегации белков и конструирования ингибиторов агрегации

Country Status (11)

Country Link
US (1) US8290713B2 (https=)
EP (1) EP2047393A1 (https=)
JP (1) JP2009545756A (https=)
KR (1) KR20090047470A (https=)
CN (1) CN101501694B (https=)
AU (1) AU2007280282B2 (https=)
CA (1) CA2657847A1 (https=)
EA (1) EA016884B1 (https=)
IL (1) IL196551A (https=)
SG (1) SG173405A1 (https=)
WO (1) WO2008015384A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN107677828A (zh) * 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
EP3242955B1 (en) 2015-01-06 2020-05-06 North Carolina State University Modeling ribosome dynamics to optimize heterologous protein production
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
CA3011719A1 (en) * 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
US10815271B2 (en) * 2016-06-29 2020-10-27 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005045442A1 (en) * 2003-11-05 2005-05-19 Cambridge University Technical Services Limited Method and apparatus for assessing polypeptide aggregation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
CA2528627A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005045442A1 (en) * 2003-11-05 2005-05-19 Cambridge University Technical Services Limited Method and apparatus for assessing polypeptide aggregation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARAVINDA SUBRAYASHASTRY ET AL.: "Structure and Assembly of Designed beta - Hairpin Peptides in Crystals as Models for beta - Sheet Aggregation", BIOCHEMISTRY; BIOCHEMISTRY FEB 24 2004, vol. 43, no. 7, 24 February 2004 (2004-02-24), pages 1832-1846, XP002456617, the whole document *
DE GROOT NATALIA SÁNCHEZ ET AL.: "Prediction of hot spots of aggregation in disease-linked polypeptides" BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 5, no. 1, 30 September 2005 (2005-09-30), page 18, XP021006180, ISSN: 1472-6807, whole document, in particular abstract, p.9, left. col. whole first paragraph, p.11., right col. second paragraph, p.12, left col. *
PAWAR A.R. ET AL.: "Prediction of ''Aggregation-prone'' and "Aggregation-susceptible" Regions in Proteins Associated with Neurodegenerative Diseases", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 350, no. 2, 8 July 2005 (2005-07-08), pages 379-392, XP004927302, ISSN: 0022-2836, whole document, in particular, abstract, p. 381, right col. - p. 382, left col., first paragraph, p. 382, left col. Third paragraph, p. 387, right col., last 2 paragraphs *

Also Published As

Publication number Publication date
WO2008015384A1 (en) 2008-02-07
IL196551A0 (en) 2009-11-18
AU2007280282A1 (en) 2008-02-07
EA200970180A1 (ru) 2009-08-28
JP2009545756A (ja) 2009-12-24
SG173405A1 (en) 2011-08-29
AU2007280282B2 (en) 2012-02-02
CA2657847A1 (en) 2008-02-07
CN101501694A (zh) 2009-08-05
US20100160602A1 (en) 2010-06-24
CN101501694B (zh) 2011-11-30
IL196551A (en) 2013-01-31
US8290713B2 (en) 2012-10-16
WO2008015384A8 (en) 2008-05-15
KR20090047470A (ko) 2009-05-12
HK1131239A1 (en) 2010-01-15
EP2047393A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
EA016884B1 (ru) Способ предсказания агрегации белков и конструирования ингибиторов агрегации
Ware et al. Role of titin in cardiomyopathy: from DNA variants to patient stratification
Leung et al. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing
Sommer et al. Structure-guided isoform identification for the human transcriptome
Redler et al. Computational approaches to understanding protein aggregation in neurodegeneration
Eulitz et al. Identification of Xin-repeat proteins as novel ligands of the SH3 domains of nebulin and nebulette and analysis of their interaction during myofibril formation and remodeling
Kontorovich Approaches to genetic screening in cardiomyopathies: practical guidance for clinicians
Seligmann Overlapping genetic codes for overlapping frameshifted genes in Testudines, and Lepidochelys olivacea as special case
Ratajczak et al. FRET-assisted determination of CLN3 membrane topology
Jensen et al. Dimerization of the Alzheimer’s disease pathogenic receptor SORLA regulates its association with retromer
Joseph et al. Disease-associated mutations in CEP120 destabilize the protein and impair ciliogenesis
Shin et al. Screening methods for identifying pharmacological chaperones
Reinoso et al. A comprehensive guide to genetic variants and post-translational modifications of cardiac troponin C
Martinez et al. TANGLED1 mediates microtubule interactions that may promote division plane positioning in maize
Rebello et al. COL11A2 as a candidate gene for vertebral malformations and congenital scoliosis
Salzillo et al. Cardiac amyloidosis: state-of-the-art review in molecular pathology
Black et al. Evaluating calmodulin–protein interactions by rapid photoactivated cross-linking in live cells metabolically labeled with photo-methionine
Wilsbacher Clinical implications of the genetic architecture of dilated cardiomyopathy
McDonnell et al. Atomic models of all major trans-envelope complexes involved in lipid trafficking in Escherichia coli constructed using a combination of AlphaFold2, AF2Complex, and membrane morphing simulations
Jossé et al. Probing the role of structural features of mouse PrP in yeast by expression as Sup35-PrP fusions
Zacco et al. Computationally Designed RNA Aptamers Enable Selective Detection of FUS Pathology in ALS
Sachsenhauser et al. Yeast tripartite biosensors sensitive to protein stability and aggregation propensity
Leinwand et al. Mutations in the sensitive giant titin result in a broken heart
Rehman et al. An EJC-independent novel isoform of MAGOH: the MAGOH-Δ37 isoform and its interactome capture
Pan et al. Distinct tau filament folds in familial frontotemporal dementia due to the MAPT S305I mutation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU